Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $33.00. Faisal Khurshid has given his Buy rating due ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback